TRA-1-60 (Podocalyxin) Monoclonal Antibody (TRA-1-60), Biotin, eBioscience | Invitrogen 13-8863-82 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

TRA-1-60 (Podocalyxin) Monoclonal Antibody (TRA-1-60), Biotin, eBioscience

catalog :

13-8863-82

quantity :

100 µg

price :

US 159

clonality :

monoclonal

host :

mouse

conjugate :

biotin

clone name :

TRA-1-60

reactivity :

human

application :

immunocytochemistry, flow cytometry

more info or order :

Invitrogen product webpage

citations: 34

Published Application/Species/Sample/Dilution	Reference
immunocytochemistry; human; 1:250	Onder T, Kara N, Cherry A, Sinha A, Zhu N, Bernt K, et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012;483:598-602 pubmed publisher
	Watanabe T, Yasuda S, Kusakawa S, Kuroda T, Futamura M, Ogawa M, et al. Multisite studies for validation and improvement of a highly efficient culture assay for detection of undifferentiated human pluripotent stem cells intermingled in cell therapy products. Cytotherapy. 2021;23:176-183 pubmed publisher
	Xing Q, El Farran C, Gautam P, Chuah Y, Warrier T, Toh C, et al. Diversification of reprogramming trajectories revealed by parallel single-cell transcriptome and chromatin accessibility sequencing. Sci Adv. 2020;6: pubmed publisher
	Simic M, Moehle E, Schinzel R, Lorbeer F, Halloran J, Heydari K, et al. Transient activation of the UPRER is an essential step in the acquisition of pluripotency during reprogramming. Sci Adv. 2019;5:eaaw0025 pubmed publisher
	Nakanishi M, Mitchell R, Benoit Y, Orlando L, Reid J, Shimada K, et al. Human Pluripotency Is Initiated and Preserved by a Unique Subset of Founder Cells. Cell. 2019;177:910-924.e22 pubmed publisher
	Ebrahimi A, Sevinç K, Gürhan Sevinç G, Cribbs A, Philpott M, Uyulur F, et al. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming. Nat Chem Biol. 2019;15:519-528 pubmed publisher
	Oleksiewicz U, Gładych M, Raman A, Heyn H, Mereu E, Chlebanowska P, et al. TRIM28 and Interacting KRAB-ZNFs Control Self-Renewal of Human Pluripotent Stem Cells through Epigenetic Repression of Pro-differentiation Genes. Stem Cell Reports. 2017;9:2065-2080 pubmed publisher
	Tsanov K, Pearson D, Wu Z, Han A, Triboulet R, Seligson M, et al. LIN28 phosphorylation by MAPK/ERK couples signalling to the post-transcriptional control of pluripotency. Nat Cell Biol. 2017;19:60-67 pubmed publisher
	Suchorska W, Augustyniak E, Richter M, Trzeciak T. Comparison of Four Protocols to Generate Chondrocyte-Like Cells from Human Induced Pluripotent Stem Cells (hiPSCs). Stem Cell Rev. 2017;13:299-308 pubmed publisher
	Debowski K, Drummer C, Lentes J, Cors M, Dressel R, Lingner T, et al. The transcriptomes of novel marmoset monkey embryonic stem cell lines reflect distinct genomic features. Sci Rep. 2016;6:29122 pubmed publisher
	Momcilovic O, Sivapatham R, Oron T, Meyer M, Mooney S, Rao M, et al. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations. PLoS ONE. 2016;11:e0154890 pubmed publisher
	Debowski K, Warthemann R, Lentes J, Salinas Riester G, Dressel R, Langenstroth D, et al. Non-viral generation of marmoset monkey iPS cells by a six-factor-in-one-vector approach. PLoS ONE. 2015;10:e0118424 pubmed publisher
	Chlon T, Hoskins E, Mayhew C, Wikenheiser Brokamp K, Davies S, Mehta P, et al. High-risk human papillomavirus E6 protein promotes reprogramming of Fanconi anemia patient cells through repression of p53 but does not allow for sustained growth of induced pluripotent stem cells. J Virol. 2014;88:11315-26 pubmed publisher
	Gkountela S, Li Z, Chin C, Lee S, Clark A. PRMT5 is required for human embryonic stem cell proliferation but not pluripotency. Stem Cell Rev. 2014;10:230-9 pubmed publisher
	Szkolnicka D, Farnworth S, Lucendo Villarin B, Storck C, Zhou W, Iredale J, et al. Accurate prediction of drug-induced liver injury using stem cell-derived populations. Stem Cells Transl Med. 2014;3:141-8 pubmed publisher
	Ackermann M, Lachmann N, Hartung S, Eggenschwiler R, Pfaff N, Happle C, et al. Promoter and lineage independent anti-silencing activity of the A2 ubiquitous chromatin opening element for optimized human pluripotent stem cell-based gene therapy. Biomaterials. 2014;35:1531-42 pubmed publisher
	Kuhn L, Liu Y, Boyd N, Dennis J, Jiang X, Xin X, et al. Developmental-like bone regeneration by human embryonic stem cell-derived mesenchymal cells. Tissue Eng Part A. 2014;20:365-77 pubmed publisher
	Choi W, Jeon H, Chung Y, Lim J, Shin D, Kim J, et al. Isolation and characterization of novel, highly proliferative human CD34/CD73-double-positive testis-derived stem cells for cell therapy. Stem Cells Dev. 2013;22:2158-73 pubmed publisher
	Chang C, Bouhassira E. Zinc-finger nuclease-mediated correction of ?-thalassemia in iPS cells. Blood. 2012;120:3906-14 pubmed publisher
	Polentes J, Jendelova P, Cailleret M, Braun H, Romanyuk N, Tropel P, et al. Human induced pluripotent stem cells improve stroke outcome and reduce secondary degeneration in the recipient brain. Cell Transplant. 2012;21:2587-602 pubmed publisher
	Cayo M, Cai J, DeLaForest A, Noto F, Nagaoka M, Clark B, et al. JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology. 2012;56:2163-71 pubmed publisher
	Chang C, Mitra K, Koya M, Velho M, Desprat R, Lenz J, et al. Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells. PLoS ONE. 2011;6:e25761 pubmed publisher
	Kuo T, Chen C, Baron D, Onder T, Loewer S, Almeida S, et al. Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol. 2011;13:1214-23 pubmed publisher
	Wada N, Wang B, Lin N, Laslett A, Gronthos S, Bartold P. Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts. J Periodontal Res. 2011;46:438-47 pubmed publisher
	Miranda Sayago J, Fernández Arcas N, Benito C, Reyes Engel A, Carrera J, Alonso A. Lifespan of human amniotic fluid-derived multipotent mesenchymal stromal cells. Cytotherapy. 2011;13:572-81 pubmed publisher
	Loewer S, Cabili M, Guttman M, Loh Y, Thomas K, Park I, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42:1113-7 pubmed publisher
	Macias M, Grande J, Moreno A, Dominguez I, Bornstein R, Flores A. Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers. Am J Obstet Gynecol. 2010;203:495.e9-495.e23 pubmed publisher
	Kamata M, Liang M, Liu S, Nagaoka Y, Chen I. Live cell monitoring of hiPSC generation and differentiation using differential expression of endogenous microRNAs. PLoS ONE. 2010;5:e11834 pubmed publisher
	Kamata M, Liu S, Liang M, Nagaoka Y, Chen I. Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter. Hum Gene Ther. 2010;21:1555-67 pubmed publisher
	Kozubenko N, Turnovcova K, Kapcalova M, Butenko O, Anderova M, Rusnakova V, et al. Analysis of in vitro and in vivo characteristics of human embryonic stem cell-derived neural precursors. Cell Transplant. 2010;19:471-86 pubmed publisher
	Chin A, Fong W, Goh L, Philp R, Oh S, Choo A. Identification of proteins from feeder conditioned medium that support human embryonic stem cells. J Biotechnol. 2007;130:320-8 pubmed
	Schopperle W, DeWolf W. The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells. 2007;25:723-30 pubmed
	Badcock G, Pigott C, Goepel J, Andrews P. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res. 1999;59:4715-9 pubmed
	Andrews P, Banting G, Damjanov I, Arnaud D, Avner P. Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma. 1984;3:347-61 pubmed

product information

Product Type :

Antibody

Product Name :

TRA-1-60 (Podocalyxin) Monoclonal Antibody (TRA-1-60), Biotin, eBioscience

Catalog # :

13-8863-82

Quantity :

100 µg

Price :

US 159

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 0.25 µg/test

Species :

Human

Clone :

TRA-1-60

Isotype :

IgM

Storage :

4° C, do not freeze

Description :

TRA-1-60 is a cell surface antigen, expressed along with SSEA-3, SSEA-4 and TRA-1-81 in human embryonic stem cells, embryonal carcinoma cells and induced pluripotent stem cells (iPS). These surface markers are lost during the differentiation process. In contrast, SSEA-1 is absent in undifferentiated human stem cells but is present on the cell surface after retinoic acid mediated differentiation.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 0.25 µg/test

Aliases :

TRA160; tra60

more info or order :

Invitrogen product webpage